Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 November 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 22 May 2013